Literature DB >> 10396366

Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome.

V Mohamed-Ali1, J H Pinkney, A Panahloo, S Cwyfan-Hughes, J M Holly, J S Yudkin.   

Abstract

OBJECTIVE: In order to examine the role of insulin-like growth factors in the pathogenesis of accelerated macrovascular disease in noninsulin-dependent diabetes mellitus (NIDDM), we investigated the relationship between the insulin resistance syndrome and the IGF axis.
DESIGN: Cross-sectional analysis of the relationship between insulin resistance syndrome variables and concentrations of IGF-1, IGF-2, IGFBP-1 and IGFBP-3 in 80 subjects with NIDDM.
RESULTS: After correcting for age, sex and body mass index, concentrations of IGFBP-1, correlated with those of HDL-cholesterol (r = 0.40; P < 0.001), triglycerides (r = -0.24; P = 0.04), insulin (r = -0.39; P < 0.001), intact proinsulin (r = -0.32; P = 0.006), des 31,32 proinsulin (r = -0.40; P = 0.001), and with insulin sensitivity (r = 0.38; P = 0.001) and PAI-1 activity (r = -0.24; P = 0.05); IGF-1 levels only correlated with those of HDL-cholesterol (r = -0.33; P = 0.005), and this was not explained by IGFBP-1 or insulin sensitivity. With additional correction for insulin, concentrations of IGFBP-1 still correlated with HDL-cholesterol (r = 0.40; P < 0.001), but not those of triglycerides or PAI-1 activity. There were no significant relationships between levels of IGF-2 and any of the variables investigated, and IGFBP-3 levels only correlated with those of total cholesterol (r = 0.24, P = 0.04).
CONCLUSIONS: In NIDDM, concentrations of IGFBP-1 are related to those of insulin, insulin sensitivity, serum lipoproteins and PAI-1 activity. The relationship between concentrations of IGFBP-1 and HDL-cholesterol is not explained by insulin. Concentrations of IGF-1 are linked to HDL-cholesterol, and this is not explained by levels of IGFBP-1. IGFBP-1 concentrations were related to PAI-1 activity, and this may be explained by insulin, which regulates the production of IGFBP-1 and PAI-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396366     DOI: 10.1046/j.1365-2265.1999.00647.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Rapid suppression of growth hormone concentration by overeating: potential mediation by hyperinsulinemia.

Authors:  Andrea S Cornford; Ariel L Barkan; Jeffrey F Horowitz
Journal:  J Clin Endocrinol Metab       Date:  2011-01-05       Impact factor: 5.958

2.  Marked differences in the IGF system that are associated with migration in comparable populations of Gujaratis living in Sandwell, UK, and Gujarat, India.

Authors:  A H Heald; S G Anderson; A Vyas; K Siddals; J Patel; A P Yates; D Bhatnagar; D Prabhakaran; E Hughes; A Rudenski; P Durrington; J M Gibson; J K Cruickshank
Journal:  Diabetologia       Date:  2005-07-22       Impact factor: 10.122

3.  Pre-diagnostic carbohydrate intake and treatment failure after radical prostatectomy for early-stage prostate cancer.

Authors:  Kyeezu Kim; Angela Kong; Robert C Flanigan; Marcus L Quek; Courtney M P Hollowell; Patricia P Vidal; Jefferey Branch; Leslie A Dean; Virgilia Macias; Andre A Kajadacsy-Balla; Marian L Fitzgibbon; Daisy Cintron; Li Liu; Vincent L Freeman
Journal:  Cancer Causes Control       Date:  2019-02-07       Impact factor: 2.506

4.  Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients.

Authors:  Giovanni Tarantino; Paolo Conca; Domenico Capone; Antonio Gentile; Giuliano Polichetti; Vincenzo Basile
Journal:  Eur J Clin Pharmacol       Date:  2006-07-14       Impact factor: 2.953

Review 5.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

6.  Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients with type 1 diabetes and its complications.

Authors:  Shangsu Lu; Sharad Purohit; Ashok Sharma; Wenbo Zhi; Mingfang He; Yiqian Wang; Chao-Jun Li; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2012-06-10

7.  Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men.

Authors:  M S Lewitt; A Hilding; C-G Ostenson; S Efendic; K Brismar; K Hall
Journal:  Diabetologia       Date:  2008-05-22       Impact factor: 10.122

8.  Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults.

Authors:  Swapnil N Rajpathak; Aileen P McGinn; Howard D Strickler; Thomas E Rohan; Michael Pollak; Anne R Cappola; Lewis Kuller; XiaoNan Xue; Anne B Newman; Elsa S Strotmeyer; Bruce M Psaty; Robert C Kaplan
Journal:  Growth Horm IGF Res       Date:  2007-09-27       Impact factor: 2.372

9.  Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis.

Authors:  Adil Rajwani; Vivienne Ezzat; Jessica Smith; Nadira Y Yuldasheva; Edward R Duncan; Matthew Gage; Richard M Cubbon; Matthew B Kahn; Helen Imrie; Afroze Abbas; Hema Viswambharan; Amir Aziz; Piruthivi Sukumar; Antonio Vidal-Puig; Jaswinder K Sethi; Shouhong Xuan; Ajay M Shah; Peter J Grant; Karen E Porter; Mark T Kearney; Stephen B Wheatcroft
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

10.  Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD.

Authors:  Elina M Petäjä; You Zhou; Marika Havana; Antti Hakkarainen; Nina Lundbom; Jarkko Ihalainen; Hannele Yki-Järvinen
Journal:  Sci Rep       Date:  2016-04-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.